Abstract:e16373 Background: Biliary tract cancer (BTC) is a heterogeneous group of diseases with dismal prognosis. The TOPAZ-1 phase III trial and KENOTE 966 reported a survival benefit with the immune checkpoint inhibitor (ICI) plus chemotherapy (GemCis,GC) in patients with advanced BTC. Consequently, immunotherapy plus chemotherapy has become a new standard care for advanced BTC. Understanding the association between genomic alterations and immunotherapy outcomes of BTC could further improve the clinical benefits. Therefore, we conducted this real-world study in China. Methods: This study included 47 patients with metastatic BTC treated with PD-1/PD-L1(ICI) antibodies in combination with chemotherapy from January 2019 to January 2023 in Medical Oncology department of Chinese PLA General Hospital. The primary endpoint was progression-free survival (PFS). The secondary endpoints included overall response rate (ORR), disease control rate (DCR). The exploration endpoint was genomic and biomarker analysis. Genomic tumor DNA was isolated from 30 patients and used for targeted next-generation sequencing genes to identify the genomic profiles. Results: 47 patients received immune checkpoint inhibitor (ICI) plus with chemotherapy in first line were enrolled in this study. The median PFS were 5.4m (95%CI,4.4-6.3), ORR and DCR was 21.3% and 83.0%, respectively. Patients were grouped into two group:AS+PD1(n=34) group and GC+ICI(n=13) group. In the AS(Albumin paclitaxel+S1)+PD1 group, mPFS was 5.0m (95%CI 3.8-6.1), ORR were 20.6% and DCR were 79.4% as we reported previously. In the GC+ ICI, mPFS was 7.9m (95%CI 4.7-11.1), ORR was 23.1% and DCR was 92.3%. There was no difference in terms of PFS, ORR and DCR between two groups. With regard to biomarker analysis, PD-L1 expression positive were 16 patients, which of mPFS were 4.2m and ORR were 18.8%, otherwise 12 patients were PDL1 expression negative, of whom mPFS were 9.1m and 33.3% as unexpected. Average TMB were 4.5mt/MB for MSS type patients. There is no difference of PFS between TMB high(>4.5mt/MB) or low(<4.5mt/MB). As for genomic analysis, the most common gene alterations were TP53(N=13, 43%))KRAS(N=8, 26.7%), NTRK1\2\3(N=8, 26.7%), IDH1/2(N=6, 20%), PIK3CA(N=6, 20%), BRCA2(N=5, 16.7%). MDM2(N=5,16.7%), BRAF(N=4,13.3%). The mutations are mainly concentrated in the DDR (20) pathway followed by the RTK-RAS (16), TP53 (13), CPF (9), FA (9), HRR (9), and PI3K (8) pathways. Compared between long term survival(PFS>5.4m)and short term survival(PFS<5.4m), MDM2 was only predictor for short survival(p<0.05). Conclusions: Compared to AS+pd-1, patients received GP+ ICI numerically had better outcomes. It seems PD-L1 and TMB were not good predictors to select patients who can more benefit from immunotherapy plus chemotherapy. MDM2 mutation suggest patients tend to less active to immunotherapy-based modality.

Efficacy and safety of camrelizumab combined with chemotherapy in the treatment of advanced biliary malignancy and associations between peripheral blood lymphocyte subsets and clinical outcomes

An Assessment of Combination of the Camrelizumab with Chemotherapy in Metastatic Biliary Tract Cancers

Efficacy and safety of camrelizumab, apatinib, and capecitabine combination therapy in advanced biliary tract cancer: a phase 2, nonrandomized, prospective study

Effectiveness and Safety of Camrelizumab in Inoperable or Advanced Non-Small Cell Lung Cancer Patients: a Multicenter Real-World Retrospective Observational Study (CTONG2004-ADV).

89P Radiotherapy Followed by Camrelizumab for Unresectable Biliary Tract Cancer: A Phase II Clinical Trial

A Phase II Study of Anti–pd-1 Antibody Camrelizumab Plus FOLFOX4 or GEMOX Systemic Chemotherapy As First-Line Therapy for Advanced Hepatocellular Carcinoma or Biliary Tract Cancer.

Camrelizumab plus gemcitabine and oxaliplatin (GEMOX) in patients with advanced biliary tract cancer: a single-arm, open-label, phase II trial

Camrelizumab Plus Oxaliplatin-Based Chemotherapy As First-Line Therapy for Advanced Biliary Tract Cancer: A Multicenter, Phase 2 Trial.

Experience with Anti-PD-1 Antibody, Camrelizumab, Monotherapy for Biliary Tract Cancer Patients and Literature Review

Efficacy and safety analysis of chemotherapy combined with immunotherapy compared with standard chemotherapy for advanced biliary tract malignant tumors

On-treatment blood TMB as predictors for camrelizumab plus chemotherapy in advanced lung squamous cell carcinoma: biomarker analysis of a phase III trial

Efficacy and safety of camrelizumab in combination with radiation and chemotherapy for recurrent or metastatic cervical cancer.

Effectiveness and tolerability of camrelizumab combined with molecular targeted therapy for patients with unresectable or advanced HCC

Efficacy and Biomarker Analysis of Nivolumab Plus Gemcitabine and Cisplatin in Patients with Unresectable or Metastatic Biliary Tract Cancers: Results from a Phase II Study

Anti-PD-1 Therapy Combined with Chemotherapy or Target Therapy in Patients with Advanced Biliary Tract Cancer in Real-World Clinical Setting

Camrelizumab combined with gemcitabine and apatinib in treating advanced PD‐L1‐positive biliary tract cancers

Genomic and Biomarker Analysis of Immunotherapy Combined with Chemotherapy Treated for Patients with Metastatic BTC Cancer: A Real World Study.

Efficacy of Camrelizumab in Advanced Non-Small-Cell Lung Cancer and Prognostic Analysis of Different PET/CT Features

Camrelizumab Plus Chemotherapy in Advanced Non-Squamous Non-Small Cell Lung Cancer: Treatment Response, Survival Pattern, and Safety

Relationship Between Peripheral Blood T Lymphocyte Subsets and Prognosis of Patients with Advanced Non-small Cell Lung Cancer Treated with Camrelizumab

Superior Survival Benefits of Triple Combination Immunotherapy Compared to Standard Chemotherapy As Second-Line Treatment for Advanced Biliary Tract Cancer: a Retrospective Analysis